Atossa Therapeutics, Inc.

ATOS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$8,692-$8,423-$6,718-$6,347
Dep. & Amort.$4$4$4$4
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$796$563$774
Change in WC$1,899-$481$192-$1,486
Other Non-Cash$784$845$0$4
Operating Cash Flow-$6,005-$7,259-$5,959-$7,051
Investing Activities
PP&E Inv.-$7$0-$9$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$7$0-$9$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$3,369
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$0$0$3,369
Forex Effect$0$0$0$0
Net Chg. in Cash-$6,012-$7,259-$5,968-$3,682
Supplemental Information
Beg. Cash$57,967$65,226$71,194$74,876
End Cash$51,955$57,967$65,226$71,194
Free Cash Flow-$6,012-$7,259-$5,968-$7,051
Atossa Therapeutics, Inc. (ATOS) Financial Statements & Key Stats | AlphaPilot